These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 3698174

  • 21. Effect of partition coefficient on the ability of nitroimidazoles to enhance the cytotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
    Hirst DG, Brown JM, Hazlehurst JL.
    Cancer Res; 1983 May; 43(5):1961-5. PubMed ID: 6682009
    [Abstract] [Full Text] [Related]

  • 22. In vivo potentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea by the radiation sensitizer benznidazole.
    Siemann DW, Morrissey S, Wolf K.
    Cancer Res; 1983 Mar; 43(3):1010-3. PubMed ID: 6825075
    [Abstract] [Full Text] [Related]

  • 23. Enhancement of the DNA cross-linking activity of nitrogen mustard by misonidazole and diethyl maleate in a mouse fibrosarcoma tumor in vivo.
    Murray D, Meyn RE.
    Cancer Res; 1984 Jan; 44(1):91-6. PubMed ID: 6690065
    [Abstract] [Full Text] [Related]

  • 24. In vivo combination of misonidazole and the chemotherapeutic agent CCNU.
    Siemann DW.
    Br J Cancer; 1981 Mar; 43(3):367-77. PubMed ID: 7225287
    [Abstract] [Full Text] [Related]

  • 25. Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations.
    Wong KH, Wallen CA, Wheeler KT.
    Int J Radiat Oncol Biol Phys; 1990 May; 18(5):1043-50. PubMed ID: 2140824
    [Abstract] [Full Text] [Related]

  • 26. Enhancement of melphalan-induced tumour cell killing by misonidazole: an interaction of competing mechanisms.
    Horsman MR, Evans JW, Brown JM.
    Br J Cancer; 1984 Sep; 50(3):305-16. PubMed ID: 6466544
    [Abstract] [Full Text] [Related]

  • 27. Drug metabolism and chemosensitization. Nitroimidazoles as inhibitors of drug metabolism.
    Workman P, Twentyman PR, Lee FY, Walton MI.
    Biochem Pharmacol; 1983 Mar 01; 32(5):857-64. PubMed ID: 6838633
    [Abstract] [Full Text] [Related]

  • 28. The advantageous use of hypoxic tumour cells in cancer therapy: identical chemosensitization by metronidazole and misonidazole at moderately elevated temperatures.
    Urano M, Wong KH, Reynolds R, Begley J.
    Int J Hyperthermia; 1995 Mar 01; 11(3):379-88. PubMed ID: 7636324
    [Abstract] [Full Text] [Related]

  • 29. Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide.
    Law MP, Hirst DG, Brown JM.
    Br J Cancer; 1981 Aug 01; 44(2):208-18. PubMed ID: 7272187
    [Abstract] [Full Text] [Related]

  • 30. In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: methotrexate, 5-fluorouracil and adriamycin.
    Tannock IF.
    Br J Cancer; 1980 Dec 01; 42(6):861-70. PubMed ID: 7459220
    [Abstract] [Full Text] [Related]

  • 31. Chemosensitization of mouse tumors by misonidazole.
    Randhawa VS, Stewart FA, Denekamp J.
    Int J Radiat Oncol Biol Phys; 1982 Dec 01; 8(3-4):671-4. PubMed ID: 7107397
    [Abstract] [Full Text] [Related]

  • 32. The pharmacokinetics in mice and dogs of nitroimidazole radiosensitizers and chemosensitizers more lipophilic than misonidazole.
    White R, Workman P, Owen L.
    Int J Radiat Oncol Biol Phys; 1982 Dec 01; 8(3-4):473-6. PubMed ID: 7107369
    [Abstract] [Full Text] [Related]

  • 33. Nitrosourea-misonidazole combination chemotherapy: effect on KHT sarcomas, marrow stem cells and gut.
    Mulcahy RT, Siemann DW, Sutherland RM.
    Br J Cancer; 1982 Jun 01; 45(6):835-42. PubMed ID: 6212075
    [Abstract] [Full Text] [Related]

  • 34. Effect of clinical levels of misonidazole on the response of tumour and normal tissues in the mouse to alkylating agents.
    Brown JM, Hirst DG.
    Br J Cancer; 1982 May 01; 45(5):700-8. PubMed ID: 7082556
    [Abstract] [Full Text] [Related]

  • 35. Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain.
    Hirst DG, Brown JM, Hazlehurst JL.
    Br J Cancer; 1982 Jul 01; 46(1):109-16. PubMed ID: 7201845
    [Abstract] [Full Text] [Related]

  • 36. Enhancement of the action of alkylating agents by single high, or chronic low doses of misonidazole.
    McNally NJ, Hinchliffe M, de Ronde J.
    Br J Cancer; 1983 Aug 01; 48(2):271-8. PubMed ID: 6882665
    [Abstract] [Full Text] [Related]

  • 37. Effect of misonidazole pretreatment on nitrogen mustard-induced DNA cross-linking in mouse tissues in vivo.
    Murray D, Meyn RE.
    Br J Cancer; 1984 Dec 01; 50(6):801-8. PubMed ID: 6498077
    [Abstract] [Full Text] [Related]

  • 38. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.
    Siemann DW, Beyers KL.
    Br J Cancer; 1993 Dec 01; 68(6):1071-9. PubMed ID: 8260357
    [Abstract] [Full Text] [Related]

  • 39. Factors influencing the chemosensitization of melphalan by misonidazole.
    Randhawa VS, Stewart FA, Denekamp J, Stratford MR.
    Br J Cancer; 1985 Feb 01; 51(2):219-28. PubMed ID: 3966979
    [Abstract] [Full Text] [Related]

  • 40. Preclinical pharmacokinetics of benznidazole.
    Workman P, White RA, Walton MI, Owen LN, Twentyman PR.
    Br J Cancer; 1984 Sep 01; 50(3):291-303. PubMed ID: 6466543
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.